MedTrace Logo

Incidence of Vivax Along the Thai Burma Border

NCT01076868 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 403

Last updated 2023-01-17

No results posted yet for this study

Summary

This is a continuous cohort study consisting of 200 participants (one third 6 months old to 5 years, one third 6 to 15 years old, one third ≥ 15 years old) i.e. a new patient will be recruited (from the same age group) for any patient who develops a Pv infection so that the cohort will always have 200 patients for 3 years. Each patient will be actively followed-up every 8 weeks until Plasmodium vivax infection occurs but the duration of follow up and the number of follow up visits for each patient will vary depending on when or if a vivax infection occurs and when the patient is recruited. Therefore, the minimum follow up period for each patient will be 6 months or time to vivax infection and the maximum will be 3 years if a patient does not get vivax infection and is recruited at the beginning of the study.

Conditions

  • Vivax Malaria

Interventions

DRUG

Primaquine

Primaquine x 14 days

Sponsors & Collaborators

  • Mahidol University

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Francois Nosten, MD · Shoklo Malaria Research Unit

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-09-02
Completion
2014-09-02

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01076868 on ClinicalTrials.gov